364 related articles for article (PubMed ID: 9308560)
1. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
Garcia C; Viehman G; Hitchcock M; Clark RE
Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
4. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
5. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
6. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.
Mentzel T; Beham A; Katenkamp D; Dei Tos AP; Fletcher CD
Am J Surg Pathol; 1998 May; 22(5):576-87. PubMed ID: 9591728
[TBL] [Abstract][Full Text] [Related]
7. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
Labonte S; Hanna W; Bandarchi-Chamkhaleh B
J Cutan Pathol; 2007 Nov; 34(11):857-60. PubMed ID: 17944726
[TBL] [Abstract][Full Text] [Related]
8. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy.
Elgart GW; Hanly A; Busso M; Spencer JM
J Am Acad Dermatol; 1999 Feb; 40(2 Pt 2):315-7. PubMed ID: 10025857
[TBL] [Abstract][Full Text] [Related]
9. Atrophic dermatofibrosarcoma protuberans: a case report and reappraisal of the literature.
Sheehan DJ; Madkan V; Strickling WA; Peterson CM
Cutis; 2004 Oct; 74(4):237-42. PubMed ID: 15551716
[TBL] [Abstract][Full Text] [Related]
10. Fibrosarcomatous Change in a Dermatofibrosarcoma Protuberans: Significance and Implications in the Differential Diagnosis of the Coexpression of S100 Protein and CD34 in Both Components.
Sabater-Marco V
Am J Dermatopathol; 2020 Jan; 42(1):71-74. PubMed ID: 31884500
[No Abstract] [Full Text] [Related]
11. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
12. Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors.
Llombart B; Monteagudo C; Sanmartín O; López-Guerrero JA; Serra-Guillén C; Poveda A; Jorda E; Fernandez-Serra A; Pellín A; Guillén C; Llombart-Bosch A
J Am Acad Dermatol; 2011 Sep; 65(3):564-575. PubMed ID: 21570152
[TBL] [Abstract][Full Text] [Related]
13. Double-headed nodules on the abdomen. Myxoid dermatofibrosarcoma protuberans (DFSP).
Kunisada M; Nagai H; Shimizu H; Yogianti F; Nishiyama S; Nishigori C
Arch Dermatol; 2011 Jul; 147(7):857-62. PubMed ID: 21768490
[No Abstract] [Full Text] [Related]
14. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
15. An unusual clinical presentation of myxoid dermatofibrosarcoma protuberans with a prominent vasculature: A potential pitfall in the diagnosis of myxoid soft tissue tumors.
Tran P; Henderson GP; McLemore M
J Cutan Pathol; 2018 Jun; 45(6):419-422. PubMed ID: 29468850
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
17. Recurrent dermatofibrosarcoma protuberans with myxoid and fibrosarcomatous changes paralleled by loss of CD34 expression.
Sato N; Kimura K; Tomita Y
J Dermatol; 1995 Sep; 22(9):665-72. PubMed ID: 8537553
[TBL] [Abstract][Full Text] [Related]
18. A firm red-brown plaque on the arm. Dermatofibrosarcoma protuberans(DFSP), pigmented variant (Bednar tumor.
Quigley EA; Marghoob AA; Busam KJ; Chen CS
Arch Dermatol; 2009 May; 145(5):589-94. PubMed ID: 19451510
[No Abstract] [Full Text] [Related]
19. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
20. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma.
Mori T; Misago N; Yamamoto O; Toda S; Narisawa Y
J Dermatol; 2008 Jul; 35(7):419-25. PubMed ID: 18705829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
